Clovis Oncology announces $300 million convertible senior notes offering and $100 million common stock offering.
Clovis Oncology, Inc. (NASDAQ:CLVS) announced on April 16 the upsizing and pricing of an underwritten public offering of $300 million aggregate principal amount of its 1.25% convertible senior notes due 2025 at a price to the public of 100% of the principal amount of the notes, before underwriting discounts and commissions. Clovis also announced the pricing of 1,837,898 shares of its common stock in an underwritten public offering at a price to the public of $54.41 per share for gross proceeds of approximately $100 million, before underwriting discounts and commissions.
The offerings closed on April 19, 2018. Willkie previously represented Clovis Oncology in its IPO and numerous subsequent equity and debt offerings. Willkie has also represented Clovis Oncology several acquisitions and licensing deals of products and businesses.
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology is headquartered in Boulder, Colorado and has additional offices in San Francisco, California and Cambridge, United Kingdom.
The Willkie team was led by partner Thomas Mark and included associates Anne Barrett, Peter Melampy and Tai Fukumoto.